Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iloperidone Safety Study in Adolescent Schizophrenia or Bipolar I Disorder
NCT05648591Phase 4Recruiting
- Sponsor
- Vanda Pharmaceuticals Inc.
- Start
- May 2023
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of iloperidone in schizophrenia, bipolar I disorder, sponsored by Vanda Pharmaceuticals Inc.. Started May 2023; status: recruiting.
02
Drugs
iloperidone
03
Conditions
schizophreniabipolar I disorder
Beyond the preview
Go deeper on NCT05648591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05648591.